April | 2010 | GlobeImmune

GlobeImmune’s Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, with the Greatest Effect in the Hardest-to-Treat Patients

April 19, 2010

Data Showing Correlation of GI-5005 Therapeutic Vaccine Treatment Response and IL-28 B Genotype Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 19, 2010 – GlobeImmune Inc. announced Phase 2b data … Continue reading →

GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to be First Therapeutic Vaccine for HCV

April 15, 2010

Final Phase 2b Data for GI-5005 in Treatment-naïve Patients Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 15, 2010 – GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, … Continue reading →